NASDAQ: GEHC
GE HealthCare
Health Care · X-Ray Apparatus & Tubes & Related Irradiation Apparatus
52-week range
Stock price
Market cap
At each fiscal year end, then the latest quarter end: closing price × shares outstanding.Figures shown are for the trailing 12 months to Sep 30, 2026. Hover or tap a column for another year.$29.6B
Show tableHide table
| Period | Market cap |
|---|---|
| FY2021, ended Dec 31, 2021 | — |
| FY2022, ended Dec 31, 2022 | $26.5B |
| FY2023, ended Dec 31, 2023 | $35.2B |
| FY2024, ended Dec 31, 2024 | $35.8B |
| FY2025, ended Dec 31, 2025 | $37.4B |
| Trailing 12 months to Sep 30, 2026 (through Q3 FY2026) | $29.6B |
Revenue
By fiscal year, then the trailing 12 months.Figures shown are for the trailing 12 months to Sep 30, 2026. Hover or tap a column for another year.$21.6B
Show tableHide table
| Period | Revenue |
|---|---|
| FY2021, ended Dec 31, 2021 | $17.6B |
| FY2022, ended Dec 31, 2022 | $18.3B |
| FY2023, ended Dec 31, 2023 | $19.6B |
| FY2024, ended Dec 31, 2024 | $19.7B |
| FY2025, ended Dec 31, 2025 | $20.6B |
| Trailing 12 months to Sep 30, 2026 (through Q3 FY2026) | $21.6B |
Net income and free cash flow
By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.Figures shown are for the trailing 12 months to Sep 30, 2026. Hover or tap a column for another year.Show tableHide table
| Period | Net income | Free cash flow |
|---|---|---|
| FY2021, ended Dec 31, 2021 | $2.25B | $1.36B |
| FY2022, ended Dec 31, 2022 | $1.92B | $1.82B |
| FY2023, ended Dec 31, 2023 | $1.57B | $1.71B |
| FY2024, ended Dec 31, 2024 | $1.99B | $1.55B |
| FY2025, ended Dec 31, 2025 | $2.08B | $1.50B |
| Trailing 12 months to Sep 30, 2026 (through Q3 FY2026) | $2.15B | $1.89B |
Cash and cash equivalents
At each fiscal year end, then the latest quarter end.Figures shown are for the trailing 12 months to Sep 30, 2026. Hover or tap a column for another year.$2.83B
Show tableHide table
| Period | Cash and cash equivalents |
|---|---|
| FY2021, ended Dec 31, 2021 | $561M |
| FY2022, ended Dec 31, 2022 | $1.44B |
| FY2023, ended Dec 31, 2023 | $2.49B |
| FY2024, ended Dec 31, 2024 | $2.87B |
| FY2025, ended Dec 31, 2025 | $4.49B |
| Trailing 12 months to Sep 30, 2026 (through Q3 FY2026) | $2.83B |
Total debt
At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.Figures shown are for the trailing 12 months to Sep 30, 2026. Hover or tap a column for another year.$9.98B
Show tableHide table
| Period | Total debt |
|---|---|
| FY2021, ended Dec 31, 2021 | — |
| FY2022, ended Dec 31, 2022 | $8.26B |
| FY2023, ended Dec 31, 2023 | $10.4B |
| FY2024, ended Dec 31, 2024 | $10.5B |
| FY2025, ended Dec 31, 2025 | $10.5B |
| Trailing 12 months to Sep 30, 2026 (through Q3 FY2026) | $9.98B |
Shares outstanding
At each fiscal year end, then the latest quarter end, adjusted for splits. Down 0.4% since 2021.Figures shown are for the trailing 12 months to Sep 30, 2026. Hover or tap a column for another year.452M
Show tableHide table
| Period | Shares outstanding |
|---|---|
| FY2021, ended Dec 31, 2021 | 454M |
| FY2022, ended Dec 31, 2022 | 454M |
| FY2023, ended Dec 31, 2023 | 455M |
| FY2024, ended Dec 31, 2024 | 457M |
| FY2025, ended Dec 31, 2025 | 456M |
| Trailing 12 months to Sep 30, 2026 (through Q3 FY2026) | 452M |
Buybacks and new shares
By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.Figures shown are for the trailing 12 months to Sep 30, 2026. Hover or tap a column for another year.Net: $148M more bought back than issued
Show tableHide table
| Period | Bought back | Paid to employees |
|---|---|---|
| FY2021, ended Dec 31, 2021 | — | $76.0M |
| FY2022, ended Dec 31, 2022 | — | $67.0M |
| FY2023, ended Dec 31, 2023 | $0 | $114M |
| FY2024, ended Dec 31, 2024 | $0 | $125M |
| FY2025, ended Dec 31, 2025 | $200M | $130M |
| Trailing 12 months to Sep 30, 2026 (through Q3 FY2026) | $300M | $152M |
Revenue (TTM)
$21.6B
+6.9% YoY
Net income (TTM)
$2.15B
−2.8% YoY
Cash
$2.83B
−29.4% YoY
Total debt
$9.98B
−18.8% YoY
Valuation
At current price- Market Cap
- $34.6B
- P/E
- 16.1×
- Forward P/E
- —. Needs analyst estimates; not available from the current data provider
- Price / Sales
- 1.6×
- Price / Book
- 3.0×
- EV / EBITDA
- 11.9×
Growth
Trailing 12 months- Revenue (TTM)
- $21.6B
- Revenue Growth YoY
- 6.9%
- Revenue CAGR 3Y
- 4.0%
- Revenue CAGR 5Y
- —. Compound annual growth over the last 5 fiscal years
- EPS Growth YoY
- −2.1%
- Net Income Growth YoY
- −2.8%
Profitability
Trailing 12 months- Gross Margin
- 39.9%
- Operating Margin
- 13.3%
- Net Margin
- 10.0%
- FCF Margin
- 8.7%
- Return on Equity
- 19.9%
Earnings
Trailing 12 months- Net Income
- $2.15B
- EPS (diluted)
- $4.73
- EBITDA
- $3.51B
- Operating Income
- $2.88B
Balance Sheet
As of Sep 30, 2026- Cash and cash equivalents
- $2.83B
- Total Debt
- $9.98B
- Net Debt
- $7.15B
- Total Assets
- $38.4B
- Total Liabilities
- $26.5B
- Shareholders' Equity
- $11.6B
Cash Flow
Trailing 12 months- Operating Cash Flow
- $2.42B
- Capital Expenditure
- $526M
- Free Cash Flow
- $1.89B
Dividends and risk
Last 12 months- Dividend Yield
- 0.2%
- Dividend / Share
- $0.15
- Beta (5Y)
- 0.84
Every ratio is calculated from the company’s reported figures.
Strength
Revenue is up 6.9% year over year, at $21.6B.
Note
Net margin of 10.0% over the last 12 months.
Note
Net debt of $7.15B is 2.0× EBITDA.
Note
Free cash flow of $1.89B, 8.7% of revenue.
Written by fixed rules from the reported figures, not by a person or an AI.
Latest report
Pro10-Q for the quarter ended Sep 30, 2026 · filed Oct 28, 2026
The score and findings for the newest report are part of CoreStock Pro, coming soon. Every earlier report is free.
Score of each annual report
0 to 100 · 60 means nothing notable · tap a column for its details
2025 · 10-K51Some concerns
10-K for the fiscal year ended Dec 31, 2025
Filed Feb 4, 2026 · Read the filing on EDGAR
- Revenue rose 4.8% to $20.6 billion and net income rose 4.6% to $2.08 billion, but Imaging and Patient Care profits fell.
- New tariffs cut operating income by about $245 million and cash flow by about $285 million. Management expects the hit to continue.
- Debt rose to $10.0 billion from $8.95 billion. The company agreed to buy Intelerad for $2.3 billion in cash.
- China sales fell 4.6%, a smaller drop than last year's 15%, as local competitors and bulk government purchasing kept up the pressure.
Business momentum
Mixed
“PCS Segment EBIT was $209 million, a decrease of $137 million due to unfavorable mix, cost inflation, including the impact of incremental tariffs, and a decline in sales volume”
Outlook
Cautious
“Should the tariffs continue at formally communicated levels, we expect to continue to see a material impact to our financial results.”
Financial stress
Low
“As of December 31, 2025, our Cash, cash equivalents, and restricted cash balance in the Consolidated Statements of Financial Position was $4,512 million.”
Tone against the previous report
About the same
Red flags
- Medium
Other
“tariffs materially impacted our Operating income by approximately $245 million and cash flows by approximately $285 million for the year ended December 31, 2025”
Positives
Contrast-agent unit (PDx) grew strongly
“PDx segment revenues were $2,900 million, growing 15.6% or $392 million as reported, driven by an increase in Organic revenue* and the acquisition of Nihon Medi-Physics Co., Ltd.”
Sales growth in US, Canada and Europe
“USCAN revenues were $9,531 million, growing 6.1% or $550 million, largely driven by growth across AVS, Imaging, and PDx segment revenues”
Steady operating cash flow
“Cash generated from operating activities in the year ended December 31, 2025 was $1,987 million”
Concerns
Imaging profit fell on rising costs
“Imaging Segment EBIT was $891 million, a decrease of $71 million due to cost inflation, including the impact of incremental tariffs”
Profit margin narrowed on an adjusted basis
“Adjusted EBIT* and Adjusted EBIT margin* were $3,155 million and 15.3%, a decrease of $56 million and 100 basis points, respectively”
Higher debt and pension shortfall
“As of December 31, 2025, we had $10,003 million of total debt compared to $8,951 million as of December 31, 2024.”
New risks since the previous report
$2.3 billion Intelerad acquisition
“on November 20, 2025, we announced an agreement to acquire Intelerad for a purchase price of $2,300 million to be paid in cash”
China limits on rare earth mineral exports
“in 2025, China significantly tightened its export controls on rare earth minerals.”
China local competition and bulk government purchasing
“increased competition from local companies and the prevalence of Volume Based Procurement policies, both of which have impacted our orders and revenues and may continue to do so.”
Foreign customers turning against US companies
“if negative sentiment towards U.S. companies influences the purchasing decisions of global customers, our business could be impacted materially.”
Biggest risks named
- Tariffs and trade protectionism
- China competition and bulk government purchasing
- About $10 billion of debt and a $4.4 billion pension shortfall
- Supply of rare earths and other raw materials
- Risks of buying and integrating companies, including Intelerad
Artificial intelligence in this business: Material to the business
How the score adds up
| Starting point | 60 | |
| Business momentum | −3 | |
| Outlook | −2 | |
| Tone against the previous report | 0 | |
| Financial stress | 0 | |
| Red flags | −1.8 | |
| New risks | −2 | |
| Score | 51 | |
Written by AI (Claude Opus 5.5) from the report’s text. 14 of 14 quotes were found word for word in the filing; the rest are left out. Not investment advice.
All scored reports
| Period | Report | Filed | Score | Momentum | Red flags |
|---|---|---|---|---|---|
| 10-Q | Oct 28, 2026 | Pro | |||
| 10-K | Feb 4, 2026 | 51 | Mixed | 1 medium | |
| 10-K | Feb 13, 2025 | 63 | Improving | None | |
| 10-K | Feb 6, 2024 | 57 | Mixed | None | |
| 10-K | Feb 15, 2023 | 55 | Mixed | None |
How these scores work
An AI model reads the management discussion, risk factors and legal sections of each report and records what they say, quoting the filing word for word. Fixed rules then turn those findings into a score from 0 to 100, where 60 means nothing notable either way. A score describes the report, not whether the stock is a good investment, and the AI may know how things turned out later, which can colour older scores. Read the methodology
From the 10-Q for Q3 FY2026 (period ended Sep 30, 2026), filed Oct 28, 2026. View filings on SEC EDGAR